Novo Nordisk Enters Bidding War to Acquire Obesity Biotech Metsera, Rivaling Pfizer

Novo Nordisk has launched a competitive bid to acquire Metsera, a biotech company specializing in obesity treatment, aiming to surpass an offer from Pfizer. The bidding war signals increased interest and competition in the obesity-focused biotech sector.